Holen Sie sich die Stockscreener-App
13.71
0.07%
0.01
Handel nachbörslich:
13.72
0.010
+0.07%
Organon Co Aktie (OGN) Neueste Nachrichten
Organon presents VTAMA analysis: Organon stock gains 1.16 percent - AD HOC NEWS
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference - Business Wire
Organon & Co. (OGN) Stock Forecasts - Yahoo Finance
Tangible book value per share of Organon & Co. – HAN:7XP - TradingView
Organon & Co. Revenue Breakdown – HAN:7XP - TradingView
Sun Pharma plans $1 billion local debt sale for loan takeout, sources say - ETPharma.com
Sun Pharma Plans Rs 10,000 Crore Rupee Debt Sale To Refinance Organon Deal: Report - NDTV Profit
Sun Pharma plans $1 billion rupee debt sale to refinance Organon acquisition loan - Firstpost
Organon Says Nduvra Cream Gets Canada Approval for Atopic Dermatitis - marketscreener.com
Sun Pharma’s Biggest Global Bet, Buys Organon in $11.75 Billion Deal; Pharma Stock Surge 7%Time to Buy? - goodreturns.in
Organon & Co. (OGN) Stock forecasts - Yahoo Finance Singapore
Precision Trading with Organon & Co. (OGN) Risk Zones - Stock Traders Daily
Why Organon (OGN) Is Getting Attention Today - Yahoo Finance
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device - Yahoo Finance
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Organon (OGN) Looks 22% Overvalued Following The MIUDELLA FDA Filing - simplywall.st
Class A Dig — Organon/Sun Pharma premature-close (May ACQ deleted; early-2027 expected) - app.dealroom.co
Organon (OGN) Wins FDA Review Acceptance For New Hormone Free Contraceptive - simplywall.st
how InvestingPro spotted Organon’s 65% gain in healthcare sector By Investing.com - Investing.com Canada
Organon Backs Women’s Health Efforts Across India - pharmacy.biz
Organon Korea, Boryung expand Atozet tie-up to co-promotion - koreabiomed.com
Organon & Co. Common Stock (NY: OGN - The Chronicle-Journal
ORGANON & CO.MIUDELLA ANTICIPATED TO BE COMMERCIALLY AVAILABLE IN LATE 2026 - Moomoo
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA - Business Wire
Responsive Playbooks and the OGN Inflection - Stock Traders Daily
Organon: A Merger-Arbitrage Hold With Limited Upside - Seeking Alpha
OGN Stock Set For Blastoff? Sun Pharma Offers 24% Premium In All-Cash Buyout Deal - Stocktwits
Sun Pharma Gets Investment-Grade Ratings From Moody's, S&P for USD 11.75 Bn Organon Deal - Medical Dialogues
Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid - Business Standard
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sun Pharma receives ratings boost over USD 11.75-billion Organon acqui - Daily Pioneer
Sun Pharma Gets Ratings Boost From Moody's, S&P Over $11.75-Bn Organon & Co Acquisition Bid - outlookbusiness.com
Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid - BusinessLine
Sun Pharma gets ratings boost from Moody's, S&P over $11.75 bn Organon & Co acquisition bid - ET Manufacturing
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid - The Economic Times
Sun Pharma Gets Ratings Boost After Organon Acquisition Bid - Rediff MoneyWiz
Organon & Co. (OGN) Edges Up 0.15% to $13.78 as Shares Trade Between Key Support and ResistanceExtension Target - careplusvn.com
Organon & Co stock hits 52-week high at $13.78 By Investing.com - Investing.com Nigeria
Organon & Co stock hits 52-week high at $13.78 - Investing.com India
Henlius - henlius.com
Organon earnings up next: Can drugmaker rebound after Q1 miss? - investing.com
Organon (OGN) Move: Ends Up by 0.07% at $13.74 on the Day; Technical Setup: the $13.05 to $14.43 Range Remains in FocusBox Spread - Vinanet
Sun Pharma completes $11.75bn financing syndication for Organon acquisition - Generics and Biosimilars Initiative
Organon (OGN) Trading: Ends Up by 0.37% at $13.73 at the Close; Next Session: the Supplied Trading Band Runs From $13.04 to $14.42 under the Current SnapshotOvernight Profile - Vinanet
Organon & Co stock hits 52-week high at 13.73 USD - Investing.com
Organon & Co. (NYSE:OGN) Reaches New 12-Month HighStill a Buy? - MarketBeat
Orographic Financial Advisors, LLC's Organon & Co(OGN) Holding History - GuruFocus
how InvestingPro’s Fair Value spotted Organon’s 69% gain potential By Investing.com - Investing.com South Africa
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):